About chrismoorecm1gmailcom

This author has not yet filled in any details.
So far chrismoorecm1gmailcom has created 29 blog entries.

AACR Abstract: A novel panel of 325 biomarkers is part of a large interconnected network representing multiple cell signaling pathways and allowing development of predictive tests for oncology drugs

2018-04-20T05:30:58+00:00

A novel panel of 325 biomarkers is part of a large interconnected network representing multiple cell signaling pathways and allowing development of predictive tests for oncology drugs We developed an algorithm based on the gene expression of tumor biopsies to identify the best combination of biomarkers to reliably predict a [...]

AACR Abstract: A novel panel of 325 biomarkers is part of a large interconnected network representing multiple cell signaling pathways and allowing development of predictive tests for oncology drugs2018-04-20T05:30:58+00:00

AACR Abstract: Technical validation of novel 325 RNA predictive biomarkers using gene expression data generated by Nanostring n-counter and Affymetrix microarray

2018-04-25T03:51:08+00:00

Technical validation of novel 325 RNA predictive biomarkers using gene expression data generated by Nanostring n-counter and Affymetrix microarray With new developments of oncology drug combinations and targeted treatments, the ability to stratify categories of patient populations and to develop companion diagnostics has become increasingly important. A panel of 325 [...]

AACR Abstract: Technical validation of novel 325 RNA predictive biomarkers using gene expression data generated by Nanostring n-counter and Affymetrix microarray2018-04-25T03:51:08+00:00

BIOARRAY Genetics Inc. Announces the Launch of a Novel Oncology Gene Panel

2018-04-26T20:49:36+00:00

BIOARRAY Genetics Inc. Announces the Launch of a Novel Oncology Gene Panel BIOARRAY Genetics Inc. announced the launch of a novel oncology gene panel, BA325, a research and development tool that accelerates drug discovery and development for cancer treatments by providing new information on cancer response to treatments. BA325 contains [...]

BIOARRAY Genetics Inc. Announces the Launch of a Novel Oncology Gene Panel2018-04-26T20:49:36+00:00

Marcia Fournier Named 2017 Women of Innovation Finalist

2018-04-26T20:48:03+00:00

Bioarray Founder & CEO, Marcia Fournier, Named 2017 Women of Innovation Finalist The Connecticut Technology Council (CTC) is pleased to announce the 50 women who have been selected as the 2017 Women of Innovation finalists for the 13th Annual Women of Innovation awards program. The Women of Innovation® program seeks to celebrate [...]

Marcia Fournier Named 2017 Women of Innovation Finalist2018-04-26T20:48:03+00:00

SABCS Abstract: A predictive test for neoadjuvant chemotherapy in breast cancer identifies a subset of triple negative patients with resistant disease and the poorest prognosis

2018-04-20T23:26:18+00:00

A predictive test for neoadjuvant chemotherapy in breast cancer identifies a subset of triple negative patients with resistant disease and the poorest prognosis Prediction of pathological complete response (pCR) for neoadjuvant treatment is an area of unmet clinical need, especially for triple negative breast cancer (TNBC) as pCR is correlated [...]

SABCS Abstract: A predictive test for neoadjuvant chemotherapy in breast cancer identifies a subset of triple negative patients with resistant disease and the poorest prognosis2018-04-20T23:26:18+00:00

Startup’s diagnostics test aims to reshape breast cancer treatment

2018-04-26T20:50:19+00:00

Startup's diagnostics test aims to reshape breast cancer treatment As founder and CEO of BioArray Therapeutics Inc., a Connecticut-based cancer diagnostics startup, Marcia Fournier has heard from hundreds of breast cancer patients and their families about the physical, emotional and financial toll that chemotherapy treatments have taken on them. "After [...]

Startup’s diagnostics test aims to reshape breast cancer treatment2018-04-26T20:50:19+00:00

SABCS Abstract: Gene expression profiles accompanying phenotypic changes during non-malignant breast epithelial cells acini formation to explain MRI phenotypes

2018-04-20T05:38:00+00:00

Gene expression profiles accompanying phenotypic changes during non-malignant breast epithelial cells acini formation to explain MRI phenotypes Magnetic resonance imaging (MRI) captures the three dimensional way in which tumors are organized in the breast, defined as imaging phenotypes in the I-SPY 1 trial. We developed a gene set based on [...]

SABCS Abstract: Gene expression profiles accompanying phenotypic changes during non-malignant breast epithelial cells acini formation to explain MRI phenotypes2018-04-20T05:38:00+00:00

Experiments that Point to a New Understanding of Cancer

2018-04-26T20:51:25+00:00

Mina Bissel: Experiment that point to a new a new understanding of cancer For decades, researcher Mina Bissell pursued a revolutionary idea -- that a cancer cell doesn't automatically become a tumor, but rather, depends on surrounding cells (its microenvironment) for cues on how to [...]

Experiments that Point to a New Understanding of Cancer2018-04-26T20:51:25+00:00

ASCO Abstract: Use of gene expression signature to predict response to combination chemotherapy in breast cancer clinical subgroups.

2018-04-20T05:51:01+00:00

Use of gene expression signature to predict response to combination chemotherapy in breast cancer clinical subgroups. Accurate stratification of patients prior to treatment with combination chemotherapy would allow non-responders to receive an alternative treatment in a timely manner and potentially improve clinical outcomes. We describe a 22-gene signature that accurately [...]

ASCO Abstract: Use of gene expression signature to predict response to combination chemotherapy in breast cancer clinical subgroups.2018-04-20T05:51:01+00:00

AACR Abstract: 22-gene signature predicts response to chemotherapy in a broad range of breast cancer subtypes

2018-04-20T05:49:05+00:00

 22-gene signature predicts response to chemotherapy in a broad range of breast cancer subtypes Only 15-25% of breast cancer patients from all histopathological subtypes currently respond to primary chemotherapy with a complete pathological response (pCR) and there is currently no test in widespread clinical use to predict whether a patient [...]

AACR Abstract: 22-gene signature predicts response to chemotherapy in a broad range of breast cancer subtypes2018-04-20T05:49:05+00:00